Table 1.
Clinical data, treatment, and outcome of 26 cases of primary large B-cell lymphomas of immune-privileged sites (including our 3 cases) diagnosed between 1968 and 2022.
| Author | Year | Sex | Age | B-Symptoms | Ataxia | Gait/ Coordination Disturbances |
Headache | Intracranial Hypertension | Nausea/Vomit | Vertigo | Vision Disturbances | Number of Lesions | Neoplastic Cells at Liquor Analysis | Steroid Therapy before Biopsy | Treatment | Outcome | Follow-Up (mo) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | White BE | 1968 | M | 56 | N | x | x | x | x | S | N | N | DOC | 0 | ||||
| 2 | Chang RH | 2009 | M | 67 | N | x | x | x | x | x | x | x | M | N | N | B, Rt | DOD | 4 |
| 3 | Chang RH | 2009 | F | 64 | N | x | x | x | S | N | N | B, Rt | DOD | 48 | ||||
| 4 | Chang RH | 2009 | M | 62 | N | x | x | x | x | x | x | x | S | N | N | B, Rt | CR | 61 |
| 5 | Weiqing L | 2010 | F | 70 | N | x | x | S | N | N | ||||||||
| 6 | Makhdoomi R | 2011 | F | 45 | N | x | x | S | N | N | C, Rt | 0 | ||||||
| 7 | Makhdoomi R | 2011 | M | 40 | N | x | S | N | N | C, Rt | DOD | 14 | ||||||
| 8 | Makhdoomi R | 2011 | F | 60 | N | x | M | N | N | C, Rt | DOD | 9 | ||||||
| 9 | Makhdoomi R | 2011 | F | 60 | N | x | S | N | N | None | DOD | 1 | ||||||
| 10 | Qiwu D | 2011 | M | 60 | N | x | x | S | N | N | C, Rt | LFU | 6 | |||||
| 11 | Datta A | 2013 | F | 55 | Y | x | x | S | Y | Y | Rt, carmustine | CR | 12 | |||||
| 12 | Bhawna J | 2015 | F | 63 | N | S | N | N | R, S, cyclophosphamide, doxorubicin, vincristine | 2 | ||||||||
| 13 | Beraldo GL | 2018 | F | 52 | N | x | x | S | N | N | ARAC, S | DOD | 3 | |||||
| 14 | Ghannam M | 2018 | M | 71 | N | x | x | x | M | N | Y | ARAC, MTX, S | SD | 1 | ||||
| 15 | Harley B | 2018 | F | 40 | N | x | S | N | N | ARAC MTX | PD | 6 | ||||||
| 16 | Franzini A | 2018 | M | 60 | N | x | x | S | N | N | LFU | 0 | ||||||
| 17 | Galarza Fortuna G | 2019 | F | 78 | N | x | S | N | N | MTX, R, Rt, temozolomide | CR | 14 | ||||||
| 18 | Sansoni GA | 2021 | F | 57 | N | x | x | x | M | N | N | ARAC, MTX, R, Rt | PR | 3 | ||||
| 19 | Sirinoglu D | 2021 | F | 58 | N | x | x | S | N | Y | MTX, S | CR | 6 | |||||
| 20 | DeRon jr N | 2022 | M | 66 | Y | x | M | Y | N | MTX, S, leucovorin. | SD | |||||||
| 21 | He M | 2022 | M | 22 | N | x | x | S | N | N | S, cyclophosphamide, epirubicin, vincristine | DOD | 9 | |||||
| 22 | He M | 2022 | M | 26 | N | x | x | S | N | N | ARAC; MTX | CR | 1 | |||||
| 23 | He M | 2022 | M | 54 | N | M | N | N | Rt | CR | 6 | |||||||
| 24 | Case n. 1 | 2013 | M | 76 | N | x | x | x | S | N | N | ARAC; MTX | CR | 72 | ||||
| 25 | Case n. 2 | 2020 | F | 65 | N | x | S | N | N | ARAC, MTX, R | CR | 26 | ||||||
| 26 | Case n. 3 | 2021 | F | 65 | N | M | N | N | ARAC, MTX, R | CR | 17 |
ARAC = cytarabine, BOMES = BLNU, vincristine, methotrexate, etoposide, and methylprednisolone, C = chemotherapy, CR = complete remission, DLBCL = diffuse large B-cell lymphoma, DOC = died of other causes, DOD = died of disease, F = female, LFU = lost to follow-up, M = male, MTX = methotrexate, N = NO, PR = partial remission, R = rituximab, Rt = radiotherapy, SD = state of disease, S = steroid, Y = yes.